Pulmonary Cell News 6.46 November 23, 2017 | |
| |
TOP STORYEncouraging Oxygen’s Natural Assault on Iron Kills Lung Cancer Cells Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health. [Press release from NYU Langone Health discussing online prepublication in Nature] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists report noninvasive introduction of 13C6-glucose via a stress-free, ad libitum liquid diet. Comparison of patient-derived lung tumor xenografts with ex vivo tumor cultures and arsenic-transformed lung cells versus xenografts revealed differential glucose metabolism that could reflect distinct tumor microenvironment. [Nat Commun] Full Article An RNA Structure-Mediated, Posttranscriptional Model of Human α-1-Antitrypsin Expression Investigators revealed that RNA structure governs a complex posttranscriptional regulatory program of α-1-antitrypsin expression. [Proc Natl Acad Sci USA] Full Article Epithelial Folliculin Is Involved in Airway Inflammation in Workers Exposed to Toluene Diisocyanate The authors investigated the involvement of folliculin (FLCN) in the pathogenesis of toluene diisocyanate-induced occupational asthma. Co-culture with peripheral blood neutrophils also induced FLCN expression and release from human airway epithelial cells. [Exp Mol Med] Full Article Krüpple-Like-Factor 4 Attenuates Lung Fibrosis via Inhibiting Epithelial-Mesenchymal Transition Researchers examined the role of Krüpple-like-factor 4 (KLF4) in pulmonary fibrosis and epithelial-mesenchymal transition. Decreased expression of KLF4 was observed in human idiopathic pulmonary fibrosis lung tissues and models of bleomycin-induced pulmonary fibrosis. [Sci Rep] Full Article LUNG CANCERScientists found that under nutrient limitation, activation of CASP8 was significantly increased in autophagy-deficient lung cancer cells, which precedes mitochondria outer membrane permeabilization, CYCS/cytochrome c release, and activation of CASP9, indicating that under such conditions the activation of CASP8 is a primary event in the initiation of apoptosis as well as essential to reduce clonogenic survival of autophagy-deficient cells. [Autophagy] Abstract The authors identified the role and molecular mechanisms of ARHGEF19 in the tumorigenesis of non-small cell lung cancer. [Int J Cancer] Abstract Investigators demonstrated that prolonged exposure of BEAS-2B cells to amorphous silica nanoparticles induced malignant transformation as indicated by enhanced cellular proliferation, anchorage-independent cell growth, and increased cell migration. [Nanotoxicology] Abstract Scientists showed that CK2α knockdown or quinalizarin significantly enhanced the radiosensitivity of various non-small cell lung cancer cells. [Sci Rep] Full Article | |
| |
REVIEWSThe authors summarize the current knowledge linking senescence-associated extracellular vesicles (EVs) to the senescence-associated secretory phenotype factor and discuss the roles of these EVs in age-related lung diseases. [Mol Aspects Med] Full Article Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
INDUSTRY NEWSGenentech announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of TECENTRIQ® and Avasti® plus chemotherapy provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death compared to Avastin plus chemotherapy in the first-line treatment of people with advanced non-squamous non-small cell lung cancer. [Genentech, Inc.] Press Release LLS Funds $46 Million in New Research to Find Cures The Leukemia & Lymphoma Society® (LLS) committed an additional $46 million to fund the most innovative science at leading medical institutions around the world, including Memorial Sloan Kettering Cancer Center in New York, Dana-Farber Cancer Institute in Boston, City of Hope in Duarte, California, and the Walter & Eliza Hall Institute of Medical Research in Australia. [The Leukemia & Lymphoma Society®] Press Release | |
| |
POLICY NEWSStill No Science Advisor at the White House Ten months into his presidency, Donald Trump has yet to name a science advisor. It’s the longest amount of time a modern president has taken to nominate someone to the position since at least 1976, when Congress established the White House’s Office of Science and Technology Policy. [MIT Technology Review] Editorial Director of HHS Scientific Fraud Office Is out after Stormy 2-Year Tenure The controversial director of the office that polices research fraud in U.S.-funded biomedical labs is temporarily moving to another agency. Kathy Partin has been removed after nearly two years as director of the U.S. Office of Research Integrity in Rockville, Maryland, according to Retraction Watch. [ScienceInsider] Editorial European Medicines Agency Will Move to Amsterdam The European Medicines Agency, charged with evaluating human and animal medicinal products for the European Union, will relocate to Amsterdam after it was selected in a draw of lots between it and Milan. [ScienceInsider] Editorial Hungary Rewards Highly Cited Scientists with Bonus Grants Some top researchers prosper in Hungary as country tries to improve its international standing in science. [Nature News] Editorial
| |
EVENTSNEW SYStem – Symposium for the Next Generation of Stem Cell Researchers Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow/Associate – Inflammation and Fibrosis (Rhode Island Hospital) Scientific Leader – Lung Repair and Regeneration (AstraZeneca) Postdoctoral Position – Lung Cancer (Helmholtz Centre for Environmental Research) Postdoctoral Fellow – Disease Mechanism (University of California, San Diego) Postdoctoral Fellow – Lung Cancer (Moffitt Cancer Center) Postdoctoral Position – Immunology & Respiratory Diseases (Boehringer Ingelheim) Faculty Position – Cancer Experimental Therapeutics (University of New Mexico) PhD Position – Pulmonary Research (Helmholtz Zentrum München) Postdoctoral Position – Immunology/Molecular Biology (Helmholtz Zentrum München) Postdoctoral Position – Lung Adenocarcinoma (University of California, San Francisco) PhD Position – Molecular Pharmacology (University of Groningen) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|